ERBB2 and breast carcinoma: Although recently published guidelines from ASCO recommended against the use of any commercially available biomarkers in early HER2-positive breast cancer,19 there has been substantial evidence of the importance of molecular subtyping in treatment decision making rather than pure recurrence risk prediction,20,21 which would be more appropriate in the era where targeted biologic agents are being developed at a rapid pace.